Premium
Pharmacotherapy for Neurodegenerative Diseases: Are We Approaching the Tipping Point?
Author(s) -
Honig PK
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.209
Subject(s) - tipping point (physics) , pharmacotherapy , disease , intensive care medicine , clinical trial , medicine , clinical pharmacology , drug development , public health , drug , pharmacology , psychiatry , pathology , electrical engineering , engineering
Neurodegenerative diseases continue to represent major unmet medical and public health needs and will increasingly strain the healthcare system as people live longer due to medical advances in other diseases. Hopefully the emergence of increased understanding of the biology of these conditions coupled with novel clinical pharmacology tools, clinical trial designs, and regulatory innovation will allow the emergence of highly effective symptomatic and disease modifying pharmacotherapies.